Sponsored Content

Advancing Gene Therapy by Solving Challenges in Scale-Up & Manufacturing

Today’s biologic drugs give the promise of breakthrough treatment options for the world’s most challenging diseases and chronic conditions. In the case of gene therapies, the impact of these treatments will only expand as they are administered to...

New Choices to Help Improve mAbs Downstream Manufacturing Efficiency: Introducing the J.T.Baker® BAKERBOND® PROchievA™ Recombinant Protein A Resin

An integrated mAbs downstream purification process featuring Avantor J.T.Baker® BAKERBOND® PROchievA™ recombinant protein A chromatography columns and resins can enable significant throughput improvement while removing of critical impurities.

Small-Molecule Matters: Integration in Drug Development

How a collaborative approach between small and large drug developers with the right CDMO can overcome critical challenges to achieve greater efficiencies in quality, time, and cost – at every stage of the small molecule drug lifecycle.

COVID-19 and What’s Next for API Sourcing?

The pandemic challenged the global supply chain instantly. Geopolitical tensions and the call for localizations and self-reliance are further adding to the complexity of today’s API souring. In this article we look on supply chain security in a...

A Cambrex Webinar - Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Dr. Craig Callahan, Project Scientist, Cambrex Edinburgh, discusses the importance of understanding crystallization processes to avoid unnecessary cost, risk and development delays.

Sponsored Content

Advancing Gene Therapy by Solving Challenges in Scale-Up & Manufacturing

New Choices to Help Improve mAbs Downstream Manufacturing Efficiency: Introducing the J.T.Baker® BAKERBOND® PROchievA™ Recombinant Protein A Resin

Small-Molecule Matters: Integration in Drug Development

COVID-19 and What’s Next for API Sourcing?

A Cambrex Webinar - Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Overcoming Challenges to Deliver Fixed Dose Combination (FDC) Drug Products

Q&A with Stephan Haitz, President, CDMO Sales & Marketing at Cambrex

A Cambrex Webinar- De-Risking the Solid Form Landscape of an API

Future focus: Our 2020 vision

Small Molecules: 2020 Vision

Digital Transformation in 2020: What Should Pharma Know?

A winning pediatric dosage formulation

Cambrex eBook - Small molecules 2.0: the bigger picture

Continuous Flow for APIs and Intermediates (Part 2)

Continuous Flow for APIs & Intermediates (Part 1)

Sponsored Content

Login Form